BLASINGLE-USEVIAL1 Generic Approved
Approved
Feb 2026
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
2/8 — Basic
RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj (human recombinant)) by Johnson & Johnson. Approved for endoglycosidase [epc]. First approved in 2026.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RYBREVANT FASPRO is a bispecific antibody (amivantamab) combined with a human recombinant hyaluronidase for subcutaneous administration. It targets EGFR and MET pathways and is designed for patients with specific solid tumors. The hyaluronidase component enables faster subcutaneous delivery compared to traditional IV infusions.
Launch
As a newly launched bispecific with subcutaneous convenience, this product has significant growth potential and will require robust commercial infrastructure and medical education teams.
Mechanism of Action
Pharmacologic Class:
Endoglycosidase
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on RYBREVANT FASPRO at launch offers early-career visibility and the chance to shape a new bispecific franchise in oncology. This is a high-impact, growth-focused opportunity with exposure to cutting-edge mechanism of action and subcutaneous delivery innovation.
Brand ManagerMedical Science Liaison (MSL)
Worked on RYBREVANT FASPRO at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.